Testing plixorafenib in people whose cancer has a BRAF gene change
Official title: A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a drug called plixorafenib in people whose cancer has a change in a gene called BRAF.
Read our full plain-language summary
What the trial team says
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors, including rare BRAF V600E-mutated solid tumors, including anaplastic thyroid, ovarian, cholangiocarcinoma or other rare cancers.
Key facts
- Registry number
- NCT05503797
- Stage of testing
- Phase 2
- Conditions studied
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
Where it is running
This trial lists 70 sites.
-
A Coruña
- Hospital Clinico Universitarlo de Santiago (Santiago de Compostela)
-
Aquitaine
- Institut Bergonie (Bordeaux)
-
Baden-Wurttemberg
- Universitätsklinikum Heidelberg (Heidelberg)
-
Barcelona
- Hospital Universitari Vall d'Hebron (Barcelona)
-
Bouches-du-Rhône
- Hôpital Nord de Marseille (Marseille)
-
California
- Precision NextGen Oncology & Research Center (Beverly Hills)
- UCSF Helen Diller Family Comprehensive Cancer Center (San Francisco)
- University of California Los Angeles Rheumatology (Westwood, Los Angeles)
-
Connecticut
- Norwalk Hospital (Norwalk)
-
England
- The Christie NHS Foundation Trust (Manchester)
-
Finistère
- Hôpital Morvan (Brest)
-
Florida
- University of Miami Hospital and Clinics (Miami)
-
Forli-Cesena
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST (Meldola)
-
France
- Institut Universitaire du Cancer de Toulouse Oncopole (Toulouse)
-
Germany
- Charité - Universitätsmedizin Berlin (Berlin)
-
Gyeonggi-do
- Catholic University of Korea Saint Vincent's Hospital (Suwon)
-
Gyeonggido
- Seoul National University Hospital (Suwon)
-
Gyeongsangnam-do
- Dong-A University Hospital (Pusan)
-
Hesse
- Krankenhaus Nordwest (Frankfurt am Main)
-
Hordaland
- Haukeland Univeritetssjukehus (Bergen)
-
Italy
- Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele (Milan)
- Istituto Europeo di Oncologia (Milan)
-
Jeollanam-do
- Chonnam National University Hwasun Hospital (Hwasun)
-
Madrid
- Hospital Infantil Universitario Niño Jesús (Madrid)
- Hospital Universitario 12 de Octubre (Madrid)
-
Maryland
- The John Hopkins Hospital (Baltimore)
- Maryland Oncology Hematology- Columbia (Rockville)
-
Massachusetts
- Tufts Medical Center (Boston)
- Massachusetts General Hospital (Boston)
- Dana-Farber Cancer Institute (Boston)
-
Minnesota
- St. Luke's Hospital (Duluth)
-
Missouri
- Mosaic Life Care at Saint Joseph - Medical Center (Saint Joseph)
-
Naples
- Istituto Nazionale Tumori IRCCS Fondazione G. Pascale (Naples)
-
Nebraska
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy (Omaha)
-
New Jersey
- Overlook Medical Center (Summit)
-
New South Wales
- Newcastle Private Hospital (New Lambton Heights)
- Orange Health Service (Orange)
- Sydney Children's Hospital Network - Randwick (Randwick)
-
New York
- Columbia University Irving Medical Center (New York)
- Memorial Sloan Kettering Cancer Center (New York)
-
North Carolina
- Atrium Health Wake Forest Baptist - Comprehensive Cancer Center (Winston-Salem)
-
Ohio
- Nationwide Children's Hospital (Colombus)
- The Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute (Columbus)
- Taylor Cancer Research Center (Maumee)
- Toledo Clinic Cancer Center (Toledo)
-
Ontario
- Sunny brook Health Sciences Centre- Bayview Campus (Toronto)
-
Oslo
- Oslo Universitetssykehus-Radiumhospitalet (Oslo)
-
Pays de la Loire Region
- Institut de Cancerologie de l'Ouest- Angers (Angers)
-
Pennsylvania
- Thomas Jefferson University (Philadelphia)
-
Quebec
- Centre Hospitalier Universitaire Sainte-Justine (Montreal)
-
Rhode Island
- Lifespan Cancer Institute - Rhode Island Hospital (Providence)
-
Seoul Teugbyeoisi
- Seoul National University Hospital (Seoul)
-
Seoul Teugbyeolsi
- Severance Hospital (Seoul)
-
Sevilla
- Hospital Universitario Virgen del Rocío (Seville)
-
Skåne County
- Skånes Universitetssjukhus (Lund)
-
South Australia
- Flinders Medical Centre (Bedford Park)
-
South Holland
- Erasmus Medisch Centrum (Rotterdam)
-
Stockholm County
- Karolinska Universitetssjukhuset (Solna)
-
Tennessee
- SCRI - TriStar Medical Group Children's Specialists (Nashville)
- SCRI Oncology Partners (Nashville)
-
Texas
- Baylor Scott & White Research Institute (Dallas)
- University of Texas MD Anderson Cancer Center (Houston)
- Baylor Scott & White Medical Center (Temple)
-
United Kingdom
- Sarah Cannon Research Institute (London)
-
Val-de-Marne
- Gustave Roussy (Villejuif)
-
Valencia
- Hospital Clinico Universitarlo de Valencia (Valencia)
-
Victoria
- The Alfred (Melbourne)
-
Washington
- University of Washington School of Medicine (Seattle)
-
West Virginia
- West Virginia University Health Sciences Campus (Morgantown)
-
Île-de-France Region
- Hôpital Universitaire Pitié Salpêtrière (Paris)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.